Pretomanid

A novel anti-tuberculosis drug.

pa-824, a bicyclic nitroimidazoles, is an anti-tuberculosis (tb) agent that exerts potent in vitro activity against mycobacterium tuberculosis with the minimal inhibition concentration (mic) ranging from 0.015 μg/ml to 0.25 μg/ml and remains actively against a wide range of isolates that are resistant to commonly used anti-tb agents leading to its successful application in the treatment of tb [1].pa-824 has been found to exhibit bactericidal activity against replicating bacilli and non-replicating bacilli under hypoxic or prolonged culture conditions in a dose dependent fashion through two possible mechanisms, which include pa-824 induced inhibition of ketomycolate synthesis and pa-824 mediated donation of nitric oxide during enzymatic nitro-reduction [1].

PA-824 is an anti-tuberculosis drug.

Pretomanid can be produced as follow

[1] ahmad z, peloquin ca, singh rp, derendorf h, tyagi s, ginsberg a, grosset jh, nuermberger el. pa-824 exhibits time-dependent activity in a murine model of tuberculosis. antimicrob agents chemother. 2011 jan;55(1):239-45. doi: 10.1128/aac.00849-10. epub 2010 oct 11.